Reconsidering the Trade-offs of Prostate Cancer Screening

Authors: Jonathan E. Shoag, Yaw A. Nyame, Roman Gulati, Ruth Etzioni, Jim C. Hu - New England Journal of Medicine, NEJM 2020 cited by 83

Shoag and colleagues review the long-term results of PSA screening from randomized trials and raise questions about whether the risk–benefit ratio is as strongly in favor of risk over benefit as currently gauged. The decline in PSA screening appears to have been precipitated in part by misinterpretations of data from randomized trials.